BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Extraordinary Shows to Long distance race on a Plane - 2Instructions to Shield Your Gold Speculation from Possible Dangers: Fundamental Protections
- 3The most effective method to Move toward Compensation Conversations for Cutting edge Practice Enrolled Attendants
- 4Vote In favor of Your Favored Language Learning Applications
- 5'We were genuinely astonished': This moss survived 9 months outside the International Space Station and could still grow on Earth
- Most loved VR Game for Wellness: Which Keeps You Dynamic?
- Pick Your Favored method of transportation
- Displaced Palestinian families suffer as heavy rains flood Gaza tent camps
- Surging measles cases are 'fire alarm' warning that other diseases could be next
- Step by step instructions to Pick the Right Sunlight powered charger Type for Your Home
- Turning into a Sharp Financial backer: Individual budget Wins
- Which Breakfast Enraptures Your Taste Buds? Vote
- Taylor Momsen explains why she quit 'Gossip Girl': 'I really didn't want to be there'
- Spotify Wrapped and Apple Music Replay are here: Top songs, albums and artists of 2025
